Ligand Pharmaceuticals, Inc. (LGND) Misses Q3 EPS by 21c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $294.60 +2.00%
Financial Fact:
Weighted average number of common shares - diluted: 23M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Weighted average number of common shares - diluted: 23M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q3 EPS of ($0.20), $0.21 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $5.7 million versus the consensus estimate of $5.9 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Leerink Starts Ligand Pharma (LGND) at Outperform
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
